Literature DB >> 10871476

Pretreatment assessment of prognostic indicators in endometrial cancer.

A Mariani1, T J Sebo, J A Katzmann, G L Keeney, P C Roche, T G Lesnick, K C Podratz.   

Abstract

OBJECTIVE: The object of this study was to assess the association of histologic, cytokinetic, and molecular variables in preoperative endometrial samples with extrauterine disease, recurrence, and survival among patients with endometrial cancer. STUDY
DESIGN: In a case-cohort study of 125 women, ploidy, S-phase fraction, proliferative index, deoxyribonucleic acid index, proliferating cell nuclear antigen, MIB-1 proliferation marker, p53 tumor suppressor gene, and cytoplasmic HER-2/neu oncogene and bcl-2 expressions were quantitated.
RESULTS: A model with only one independent term predicted progression-free survival; that variable was p53 (P <. 0001; relative risk, 5.60). A model with two independent terms predicted disease-related survival; these variables were p53 (P =. 0002; relative risk, 7.39) and MIB-1 (P =.03; relative risk, 3.27). Among patients with tumors with both p53 and MIB-1 expression exceeding 33%, a total of 32% had died of disease by 2 years. A model for predicting extrauterine disease selected two independent variables: p53 (odds ratio, 3.20; P =.01) and ploidy (odds ratio, 2. 16; P =.04). An advanced surgical stage was encountered in 26% to 35% of cases in which either the p53 expression exceeded 33% or the deoxyribonucleic acid content was nondiploid and in 53% of cases in which both variables were unfavorable.
CONCLUSIONS: Preoperative evaluation of quantifiable cytokinetic and molecular variables can assist in identifying tumor types that are predisposed toward a more aggressive clinical course.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10871476     DOI: 10.1067/mob.2000.107328

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  7 in total

1.  External validation of a nomogram predicting overall survival of patients diagnosed with endometrial cancer.

Authors:  Stephan Polterauer; Qin Zhou; Christoph Grimm; Veronika Seebacher; Alexander Reinthaller; Gerda Hofstetter; Nicole Concin; Mario M Leitao; Richard R Barakat; Nadeem R Abu-Rustum; Alexia Iasonos
Journal:  Gynecol Oncol       Date:  2012-03-23       Impact factor: 5.482

Review 2.  Molecular alterations in the pathogenesis of endometrial adenocarcinoma. Therapeutic implications.

Authors:  Laura Cerezo; Higinia Cárdenes; Helen Michael
Journal:  Clin Transl Oncol       Date:  2006-04       Impact factor: 3.405

3.  Correlation between protein expression of PTEN in human pancreatic cancer and the proliferation, infiltration, metastasis and prognosis.

Authors:  Jing Tao; Jiongxin Xiong; Tao Li; Zhiyong Yang; Xiaohui Li; Kai Li; Heshui Wu; Chunyou Wang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2006

4.  P53 and BCL-2 as prognostic markers in endometrial carcinoma.

Authors:  Márcia L M Appel; Maria I Edelweiss; James Fleck; Luis F Rivero; Waldemar A Rivoire; Heleusa I Mônego; Ricardo Dos Reis
Journal:  Pathol Oncol Res       Date:  2008-04-09       Impact factor: 3.201

5.  DNA ploidy in curettage specimens identifies high-risk patients and lymph node metastasis in endometrial cancer.

Authors:  T S Njølstad; J Trovik; T S Hveem; M L Kjæreng; W Kildal; M Pradhan; J Marcickiewicz; S Tingulstad; A C Staff; H K Haugland; R Eraker; K Oddenes; J A Rokne; J Tjugum; M S Lode; F Amant; H M Werner; H B Salvesen; H E Danielsen
Journal:  Br J Cancer       Date:  2015-04-21       Impact factor: 7.640

Review 6.  What Is the Best Preoperative Imaging for Endometrial Cancer?

Authors:  Ingfrid S Haldorsen; Helga B Salvesen
Journal:  Curr Oncol Rep       Date:  2016-04       Impact factor: 5.075

7.  Less Invasive Endometrial Cancer Surgery with Extraperitoneal Pelvic and Para-aortic Lymphadenectomy via a Small Midline Abdominal Incision and the Retroperitoneal Approach.

Authors:  Shinichi Komiyama; Chiaki Takeya; Rena Takahashi; Sumito Nagasaki; Kaneyuki Kubushiro
Journal:  J Cancer       Date:  2016-04-29       Impact factor: 4.207

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.